308 related articles for article (PubMed ID: 9816040)
21. Cathepsins B and L are markers for clinically invasive types of meningiomas.
Strojnik T; Zidanik B; Kos J; Lah TT
Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551
[TBL] [Abstract][Full Text] [Related]
22. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma.
Dohchin A; Suzuki JI; Seki H; Masutani M; Shiroto H; Kawakami Y
Cancer; 2000 Aug; 89(3):482-7. PubMed ID: 10931446
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
24. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.
Fernö M; Baldetorp B; Borg A; Brouillet JP; Olsson H; Rochefort H; Sellberg G; Sigurdsson H; Killander D
Eur J Cancer; 1994; 30A(14):2042-8. PubMed ID: 7857700
[TBL] [Abstract][Full Text] [Related]
25. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
26. Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
Lah TT; Nanni I; Trinkaus M; Metellus P; Dussert C; De Ridder L; Rajcević U; Blejec A; Martin PM
J Neurosurg; 2010 May; 112(5):940-50. PubMed ID: 19747051
[TBL] [Abstract][Full Text] [Related]
27. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen.
Billgren AM; Rutqvist LE; Johansson H; Hägerström T; Skoog L
Eur J Cancer; 2000 Jul; 36(11):1374-80. PubMed ID: 10899650
[TBL] [Abstract][Full Text] [Related]
28. [Role and behavior of cathepsin B and cathepsin L in gastric cancer].
Herszényi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Rugge M; Cardin R; Naccarato R; Farinati F
Orv Hetil; 1995 Jun; 136(25):1315-8. PubMed ID: 7596589
[TBL] [Abstract][Full Text] [Related]
29. Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC).
Lah TT; Calaf G; Kalman E; Shinde BG; Russo J; Jarosz D; Zabrecky J; Somers R; Daskal I
Biol Chem Hoppe Seyler; 1995 Jun; 376(6):357-63. PubMed ID: 7576229
[TBL] [Abstract][Full Text] [Related]
30. [The prognostic significance of cathepsin D in primary breast cancer].
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Schaeffer HJ; Stützer H; Bolte A
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):545-51. PubMed ID: 8001750
[TBL] [Abstract][Full Text] [Related]
31. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
Pujol P; Maudelonde T; Daures JP; Rouanet P; Brouillet JP; Pujol H; Rochefort H
Cancer; 1993 Mar; 71(6):2006-12. PubMed ID: 8443752
[TBL] [Abstract][Full Text] [Related]
32. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance.
Russo A; Bazan V; Gebbia N; Pizzolanti G; Tumminello FM; Dardanoni G; Ingria F; Restivo S; Tomasino RM; Leto G
Cancer; 1995 Nov; 76(10):1757-64. PubMed ID: 8625044
[TBL] [Abstract][Full Text] [Related]
33. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer cells express cathepsins B and L but not cathepsins K or H.
Ishibashi O; Mori Y; Kurokawa T; Kumegawa M
Cancer Biochem Biophys; 1999 Jul; 17(1-2):69-78. PubMed ID: 10738903
[TBL] [Abstract][Full Text] [Related]
36. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
37. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
39. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
40. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells.
Klose A; Zigrino P; Dennhöfer R; Mauch C; Hunzelmann N
Anal Biochem; 2006 Jun; 353(1):57-62. PubMed ID: 16620747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
